Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (741-750 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|May 7, 2026
A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodiesLihua Shi, Minseon Cho, Motohiko Nishida, et al.
Mabs|March 11, 2017
Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodiesRong Yang, Tushar Jain, Heather Lynaugh, et al.
Mabs|January 5, 2010
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMelarkode S Ramakrishnan, Anand Eswaraiah, Tania Crombet, et al.
Mabs|December 22, 2016
Optimizing assembly and production of native bispecific antibodies by codon de-optimizationGiovanni Magistrelli, Yves Poitevin, Florence Schlosser, et al.
Mabs|October 28, 2016
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cellsKatharine D Grugan, Keri Dorn, Stephen W Jarantow, et al.
Mabs|January 6, 2017
Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptorJennifer D Könitzer, Shreya Pramanick, Qi Pan, et al.
Mabs|December 23, 2016
Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)Juyong Hong, Yuhwa Lee, Changsoo Lee, et al.
Mabs|February 5, 2014
In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturationBing Li, Ashley E Fouts, Katharina Stengel, et al.
Mabs|February 5, 2014
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibodyCéline Monnet, Sylvie Jorieux, Nathalie Souyris, et al.
Mabs|February 5, 2014
Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potencyLouise Saul, Debra H Josephs, Keith Cutler, et al.
Pageof 184

Showing results (741-750 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|May 7, 2026
A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodiesLihua Shi, Minseon Cho, Motohiko Nishida, et al.
Mabs|March 11, 2017
Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodiesRong Yang, Tushar Jain, Heather Lynaugh, et al.
Mabs|January 5, 2010
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMelarkode S Ramakrishnan, Anand Eswaraiah, Tania Crombet, et al.
Mabs|December 22, 2016
Optimizing assembly and production of native bispecific antibodies by codon de-optimizationGiovanni Magistrelli, Yves Poitevin, Florence Schlosser, et al.
Mabs|October 28, 2016
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cellsKatharine D Grugan, Keri Dorn, Stephen W Jarantow, et al.
Mabs|January 6, 2017
Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptorJennifer D Könitzer, Shreya Pramanick, Qi Pan, et al.
Mabs|December 23, 2016
Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)Juyong Hong, Yuhwa Lee, Changsoo Lee, et al.
Mabs|February 5, 2014
In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturationBing Li, Ashley E Fouts, Katharina Stengel, et al.
Mabs|February 5, 2014
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibodyCéline Monnet, Sylvie Jorieux, Nathalie Souyris, et al.
Mabs|February 5, 2014
Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potencyLouise Saul, Debra H Josephs, Keith Cutler, et al.
Pageof 184